PURPOSE OF REVIEW: Breast cancer-related lymphedema (BCRL) is a chronic, adverse, and much feared complication of breast cancer treatment, which affects approximately 20% of patients following breast cancer treatment. BCRL has a tremendous impact on breast cancer survivors, including physical impairments and significant psychological consequences. The intent of this review is to discuss recent studies and analyses regarding the risk factors, diagnosis, prevention through early screening and intervention, and management of BCRL. RECENT FINDINGS: Highly-evidenced risk factors for BCRL include axillary lymph node dissection, lack of reconstruction, radiation to the lymph nodes, high BMI at diagnosis, weight fluctuations during and after treatment, subclinical edema within and beyond 3 months after surgery, and cellulitis in the at-risk arm. Avoidance of potential risk factors can serve as a method of prevention. Through establishing a screening program by which breast cancer patients are measured pre-operatively and at follow-ups, are objectively assessed through a weight-adjusted analysis, and are clinically assessed for signs and symptoms, BCRL can be tracked accurately and treated effectively. Management of BCRL is done by a trained professional, with research mounting towards the use of compression bandaging as a first line intervention against BCRL. Finally, exercise is safe for breast cancer patients with and without BCRL and does not incite or exacerbate symptoms of BCRL. SUMMARY: Recent research has shed light on BCRL risk factors, diagnosis, prevention, and management. We hope that education on these aspects of BCRL will promote an informed, consistent approach and encourage additional research in this field to improve patient outcomes and quality of life in breast cancer survivors.
PURPOSE OF REVIEW: Breast cancer-related lymphedema (BCRL) is a chronic, adverse, and much feared complication of breast cancer treatment, which affects approximately 20% of patients following breast cancer treatment. BCRL has a tremendous impact on breast cancer survivors, including physical impairments and significant psychological consequences. The intent of this review is to discuss recent studies and analyses regarding the risk factors, diagnosis, prevention through early screening and intervention, and management of BCRL. RECENT FINDINGS: Highly-evidenced risk factors for BCRL include axillary lymph node dissection, lack of reconstruction, radiation to the lymph nodes, high BMI at diagnosis, weight fluctuations during and after treatment, subclinical edema within and beyond 3 months after surgery, and cellulitis in the at-risk arm. Avoidance of potential risk factors can serve as a method of prevention. Through establishing a screening program by which breast cancerpatients are measured pre-operatively and at follow-ups, are objectively assessed through a weight-adjusted analysis, and are clinically assessed for signs and symptoms, BCRL can be tracked accurately and treated effectively. Management of BCRL is done by a trained professional, with research mounting towards the use of compression bandaging as a first line intervention against BCRL. Finally, exercise is safe for breast cancerpatients with and without BCRL and does not incite or exacerbate symptoms of BCRL. SUMMARY: Recent research has shed light on BCRL risk factors, diagnosis, prevention, and management. We hope that education on these aspects of BCRL will promote an informed, consistent approach and encourage additional research in this field to improve patient outcomes and quality of life in breast cancer survivors.
Entities:
Keywords:
Breast cancer-related lymphedema; Diagnosis; Management; Prevention; Risk factors; Survivorship
Authors: Fangdi Sun; Melissa N Skolny; Meyha N Swaroop; Bhupendra Rawal; Paul J Catalano; Cheryl L Brunelle; Cynthia L Miller; Alphonse G Taghian Journal: Breast Cancer Res Treat Date: 2016-05-06 Impact factor: 4.872
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Atilla Soran; Tolga Ozmen; Kandace P McGuire; Emilia J Diego; Priscilla F McAuliffe; Marguerite Bonaventura; Gretchen M Ahrendt; Lori DeGore; Ronald Johnson Journal: Lymphat Res Biol Date: 2014-12 Impact factor: 2.589
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Prue Cormie; Benjamin Singh; Sandi Hayes; Jonathan M Peake; Daniel A Galvão; Dennis R Taaffe; Nigel Spry; Kazunori Nosaka; Bruce Cornish; Kathryn H Schmitz; Robert U Newton Journal: Integr Cancer Ther Date: 2015-11-17 Impact factor: 3.279
Authors: Anna K Polomska; Steven T Proulx; Davide Brambilla; Daniel Fehr; Mathias Bonmarin; Simon Brändli; Mirko Meboldt; Christian Steuer; Tsvetina Vasileva; Nils Reinke; Jean-Christophe Leroux; Michael Detmar Journal: JCI Insight Date: 2019-02-21
Authors: Cheryl L Brunelle; Meyha N Swaroop; Melissa N Skolny; Maria S Asdourian; Hoda E Sayegh; Alphonse G Taghian Journal: Phys Ther Date: 2018-06-01
Authors: Rachelle Crescenzi; Paula M Donahue; Vaughn G Braxton; Allison O Scott; Helen B Mahany; Sarah K Lants; Manus J Donahue Journal: NMR Biomed Date: 2018-10-12 Impact factor: 4.044
Authors: Rachelle Crescenzi; Paula M C Donahue; Maria Garza; Chelsea A Lee; Niral J Patel; Victoria Gonzalez; R Sky Jones; Manus J Donahue Journal: Breast Cancer Res Treat Date: 2021-10-23 Impact factor: 4.624